Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer

Cancer Prevention Research

Volumn 4, Issue 10, 2011, Pages 1590-1598

  Heymach, John V ^a   Shackleford, Terry J ^a   Tran, Hai T ^a   Yoo, Suk Young ^a   Do, Kim Anh ^a   Wergin, Melanie ^b   Saintigny, Pierre ^a   Vollmer, Robin T ^c   Polascik, Thomas J ^d   Snyder, Denise C ^d   Ruffin IV, Mack T ^e   Yan, Shaoyu ^a   Dewhirst, Mark ^c   Kunnumakkara, Ajaikumar B ^e   Aggarwal, Bharat B ^a   Demark Wahnefried, Wendy ^a,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CHOLESTEROL; COLONY STIMULATING FACTOR 1; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

AGED; ANGIOGENESIS INDUCING AGENTS; CYTOKINES; DIET, FAT-RESTRICTED; DIETARY SUPPLEMENTS; FLAX; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; MALE; NF-KAPPA B; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WEIGHT LOSS;

EID: 80053894472     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0136     Document Type: Article

References (52)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81. (Pubitemid 36886244)
3. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer 2004;101:2371-490. (Pubitemid 39505434)
4. Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2006;56:254-81;quiz 313-4.
5. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977-83. (Pubitemid 44664277)
6. Van Patten CL, de Boer JG, Tomlinson Guns ES. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence. J Urol 2008;180:2314-21; discussion 721-2.
7. Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, et al. Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol 2010;183;345-50.
8. Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, et al. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res 2009;2:557-65.
9. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004;82:434-48. (Pubitemid 39044283)
10. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203-8.
11. Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, et al. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 2009;138:961-75.
12. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169-80. (Pubitemid 46693756)
13. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004;110:1564-71. (Pubitemid 39297977)
14. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011;4:329-46.
15. Hursting SD. Inflammatory talk: linking obesity, NF-κB and aromatase. Cancer Prev Res 2011;4:285-7.
16. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004;12:962-71.
17. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208.
18. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol Res 2006;55:233-44.
19. Garcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, Hamid Q, et al. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol 1996;157:5613-26. (Pubitemid 126448985)
20. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-56. (Pubitemid 26193013)
21. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002;51:1319-36. (Pubitemid 34826596)
22. Jiao P, Chen Q, Shah S, Du J, Tao B, Tzameli I, et al. Obesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. Diabetes 2009;58:104-15.
23. Adlercreutz H, Mazur W, Bartels P, Elomaa V, Watanabe S, Wahala K, et al. Phytoestrogens and prostate disease. J Nutr 2000;130:658S-9S. (Pubitemid 30118089)
24. Borriello SP, Setchell KD, Axelson M, Lawson AM. Production and metabolism of lignans by the human faecal flora. J Appl Bacteriol 1985;58:37-43. (Pubitemid 15136128)
25. Lin X, Switzer BR, Demark-Wahnefried W. Effect of mammalian lignans on the growth of prostate cancer cell lines. Anticancer Res 2001;21:3995-9. (Pubitemid 34229275)
26. Chen LH, Fang J, Li H, Demark-Wahnefried W, Lin X. Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway. Mol Cancer Ther 2007;6:2581-90. (Pubitemid 47480424)
27. Chen LH, Fang J, Sun Z, Li H, Wu Y, Demark-Wahnefried W, et al. Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells. J Nutr 2009;139:653-9.
28. Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MTt, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008;17:3577-87.
29. Demark-Wahnefried W, George SL, Switzer BR, Snyder DC, Madden JF, Polascik TJ, et al. Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials 2008;5:262-72.
30. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007;67:3853-61. (Pubitemid 46762173)
31. Kopetz S, HoffPM, Morris JS, Wolff RA, Eng C, Glover KY, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453-9.
32. Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28:193-201.
33. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, et al. NFkappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007;13:62-9. (Pubitemid 46067387)
34. Huang CY, Lee CY, Chen MY, Yang WH, Chen YH, Chang CH, et al. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell Physiol 2009;221:204-12.
35. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175-83. (Pubitemid 46718402)
36. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
37. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-86. (Pubitemid 39457982)
38. Carlsen H, Haugen F, Zadelaar S, Kleemann R, Kooistra T, Drevon CA, et al. Diet-induced obesity increases NF-kappaB signaling in reporter mice. Genes Nutr 2009;4:215-22.
39. Aljada A, Mohanty P, Ghanim H, Abdo T, Tripathy D, Chaudhuri A, et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 2004;79:682-90. (Pubitemid 41103915)
40. Taylor CT, Cummins EP. The role of NF-kappaB in hypoxia-induced gene expression. Ann N Y Acad Sci 2009;1177:178-84.
41. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital Database Study Group. J Clin Oncol 2004;22:446-53. (Pubitemid 41079773)
42. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007;29:88-97. (Pubitemid 47229642)
43. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86:s843-57.
44. Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 1997;4:211-32. (Pubitemid 127674006)
45. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002;99:10730-5.
46. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 1997;67:147-54. (Pubitemid 27188010)
47. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 2008;68:11-9.
48. Tymchuk CN, Barnard RJ, Heber D, Aronson WJ. Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. J Urol 2001;166:1185-9. (Pubitemid 32751066)
49. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985;318:665-7. (Pubitemid 16172416)
50. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
51. Salcedo R, Young HA, Ponce ML, Ward JM, Kleinman HK, Murphy WJ, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol 2001;166:7571-8. (Pubitemid 32525638)
52. Vasudevan AR, Wu H, Xydakis AM, Jones PH, Smith EO, Sweeney JF, et al. Eotaxin and obesity. J Clin Endocrinol Metab 2006;91:256-61. (Pubitemid 43069146)